MedTrace Logo

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

NCT03610971 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-04-02

No results posted yet for this study

Summary

The purpose of this study is to determine if adding Ruxolitinib to a Tyrone Kinase Inhibitor (TKI), prior to a second attempt at stopping a TKI will lead to prolonged treatment free remission (TFR).

Conditions

  • Chronic Phase Chronic Myeloid Leukemia
  • Chronic Myeloid Leukemia, Chronic Phase

Interventions

DRUG

Ruxolitinib

Ruxolitinib: 15 mg by mouth (PO) twice a day (BID).

DRUG

BCR-ABL Tyrosine Kinase Inhibitor (TKI)

The BCR-ABL TKIs that will be used include imatinib, dasatinib, nilotinib or bosutinib.

Sponsors & Collaborators

  • H. Jean Khoury Cure CML Consortium

    collaborator OTHER

  • Incyte Corporation

    collaborator INDUSTRY

  • H. Lee Moffitt Cancer Center and Research Institute

    lead OTHER

Principal Investigators

  • Javier Pinilla-Ibarz, MD, PhD · H. Lee Moffitt Cancer Center and Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-19
Primary Completion
2025-09-25
Completion
2026-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03610971 on ClinicalTrials.gov